Evolution of antibody immunity to SARS-CoV-2.
Christian Gaebler,Zijun Wang,Julio C. C. Lorenzi,Frauke Muecksch,Shlomo Finkin,Minami Tokuyama,Alice Cho,Mila Jankovic,Dennis Schaefer-Babajew,Thiago Y. Oliveira,Melissa Cipolla,Charlotte Viant,Christopher O. Barnes,Yaron Bram,Gaëlle Breton,Thomas Hagglof,Pilar Mendoza,Arlene Hurley,Martina Turroja,Kristie Gordon,Katrina G. Millard,Victor A. Ramos,Fabian Schmidt,Yiska Weisblum,Divya Jha,Michael Tankelevich,Gustavo Martinez-Delgado,Jim Yee,Roshni Patel,Juan Dizon,Cecille Unson-O'Brien,Irina Shimeliovich,Davide F. Robbiani,Zhen Zhao,Anna Gazumyan,Robert E. Schwartz,Theodora Hatziioannou,Pamela J. Bjorkman,Saurabh Mehandru,Paul D. Bieniasz,Paul D. Bieniasz,Marina Caskey,Michel C. Nussenzweig,Michel C. Nussenzweig +43 more
Reads0
Chats0
TLDR
In this article, the authors report on the humoral memory response in a cohort of 87 individuals assessed at 1.3 and 6.2 months after infection with SARS-CoV-2.Abstract:
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected 78 million individuals and is responsible for over 1.7 million deaths to date. Infection is associated with the development of variable levels of antibodies with neutralizing activity, which can protect against infection in animal models1,2. Antibody levels decrease with time, but, to our knowledge, the nature and quality of the memory B cells that would be required to produce antibodies upon reinfection has not been examined. Here we report on the humoral memory response in a cohort of 87 individuals assessed at 1.3 and 6.2 months after infection with SARS-CoV-2. We find that titres of IgM and IgG antibodies against the receptor-binding domain (RBD) of the spike protein of SARS-CoV-2 decrease significantly over this time period, with IgA being less affected. Concurrently, neutralizing activity in plasma decreases by fivefold in pseudotype virus assays. By contrast, the number of RBD-specific memory B cells remains unchanged at 6.2 months after infection. Memory B cells display clonal turnover after 6.2 months, and the antibodies that they express have greater somatic hypermutation, resistance to RBD mutations and increased potency, indicative of continued evolution of the humoral response. Immunofluorescence and PCR analyses of intestinal biopsies obtained from asymptomatic individuals at 4 months after the onset of coronavirus disease 2019 (COVID-19) revealed the persistence of SARS-CoV-2 nucleic acids and immunoreactivity in the small bowel of 7 out of 14 individuals. We conclude that the memory B cell response to SARS-CoV-2 evolves between 1.3 and 6.2 months after infection in a manner that is consistent with antigen persistence.read more
Citations
More filters
Journal ArticleDOI
B lymphocytes in COVID-19: a tale of harmony and discordance
Amir Hossein Mansourabadi,Azin Aghamajidi,Fatemeh Keshavarz,Ali Moazzeni,Fahimeh Lavi Arab,Arezoo Rajabian,Mona Roozbehani,Reza Falak,Fatemeh Faraji,Reza Jafari +9 more
TL;DR: In this article , the authors present the latest findings on the interaction between SARS-CoV-2 and B lymphocytes during COVID-19 infection and show that some individuals with B cell immunodeficiency have shown less production of the cytokine IL-6, resulting in a better disease outcome.
Journal ArticleDOI
Evaluating Johnson and Johnson COVID-19 Vaccination Outcomes in a Low-Income Hispanic Population
TL;DR: A pilot study was performed at a low-income emergency care clinic to assess the humoral immune response to the Johnson & Johnson (J&J) COVID-19 vaccine (Ad26.COV2.S) as mentioned in this paper .
Journal ArticleDOI
Simultaneous Quantitative SARS-CoV-2 Antigen and Host Antibody Detection and Pre-Screening Strategy at the Point of Care
Kritika Srinivasan Rajsri,Michael P. McRae,Nicolaos Christodoulides,Isaac P Dapkins,Glennon W. Simmons,Hanover Matz,Helen Dooley,David Fenyö,John T. McDevitt +8 more
TL;DR: In this paper , the authors described an improved COVID-19 screening strategy, comprising predictive algorithms and concurrent, rapid, accurate, and quantitative SARS-CoV-2 antigen and host antibody testing strategy, at point of care (POC).
Journal ArticleDOI
Researching COVID to Enhance Recovery (RECOVER) adult study protocol: Rationale, objectives, and design
Leora I. Horwitz,Tanayott Thaweethai,Shari B. Brosnahan,Mine S. Cicek,Megan Fitzgerald,Jason D Goldman,Rachel Hess,Sally Hodder,Vanessa L. Jacoby,Michael I. Jordan,Jerry A. Krishnan,Adeyinka O. Laiyemo,Torri D. Metz,Lauren R. Nichols,Rachel E. Patzer,Nora G. Singer,Lauren E. Stiles,Barbara S. Taylor,Heather Algren,K. Anglin,Lisa Aponte-Soto,Hassan Ashktorab,Ingrid V. Bassett,Brahmchetna Bedi,Nahid Bhadelia,Christian Bime,Marie-Abele Bind,Lora Jane Black,Andra L. Blomkalns,H. B. Brom,Mario Castro,James Chan,Alexander W. Charney,Li Q. Chen,Peter Chen,David Chestek,Lori B Chibnik,Dominic C. Chow,Helen Y. Chu,Rebecca G. Clifton,Shelby Collins,Maged M. Costantine,Sushma K. Cribbs,Steven G. Deeks,John D. Dickinson,Sarah E. Donohue,Matthew S Durstenfeld,Ivette F. Emery,Kristine M. Erlandson,Julio C. Facelli,Rachael M Farah-Abraham,Aloke V. Finn,Valerie J. Flaherman,J. Fleurimont,Vivian Fonseca,Emily J. Gallagher,Jennifer C. Gander,Maria Laura Gennaro,Kelly S. Gibson,Mi Soon Go,Steven N. Goodman,Joey P. Granger,Frank L. Greenway,John W. Hafner,Jenny E. Han,Michelle Harkins,Kristine Hauser,James R. Heath,On Ho,Matthew Hoffman,Susan E. Hoover,Carol R. Horowitz,Priscilla Y. Hsue,B. Hughes,Prasanna Jagannathan,Judith A. James,Janice N. John,Sarah E. Jolley,Suzanne E. Judd,Joy J Juskowich,Diane G. Kanjilal,Elizabeth W. Karlson,Stuart D. Katz,J. Daniel Kelly,Sara Kelly,Arthur Y. Kim,John P. Kirwan,K. Knox,Andre Kumar,Michelle F. Lamendola-Essel,Margaret Lanca,R. Craig Lefebvre,Bruce D. Levy,Janet Lin,Jennifer Logue,Michele Longo,Carlos A. Luciano,Karen Lutrick,Shahdi Malakooti,Gail Mallett,Gabrielle Maranga,Jai G Marathe,Vincent C. Marconi,Gailen D. Marshall,Jeffrey N. Martin,Heidi T May,Grace A. McComsey,Dylan McDonald,Hector Mendez-Figueroa,Lucio Miele,Murray A. Mittleman,Sindhu Mohandas,C. Mouchati,Janet Mullington,Girish N. Nadkarni,Erica R. Nahin,Robert B. Neuman,Janko Ž Nikolich,Ighovwerha Ofotokun,Princess U. Ogbogu,Anna Palatnik,Kristy Palomares,Tanyalak Parimon,Samuel Parry,Sairam Parthasarathy,Thomas L. Patterson,Ann Pearman,Michael J. Peluso,Priscilla Pemu,Christian M. Pettker,Beth A. Plunkett,Kristen Pogreba-Brown,Athena Poppas,J. Zachary Porterfield,John G. Quigley,Davin K. Quinn,Hengameh H. Raissy,Candida J. Rebello,Uma M. Reddy,Rebecca Reece,H. T. Reeder,Franz Rischard,Johana M. Rosas,Clifford J. Rosen,Nadine Rouphael,Dwight J. Rouse,Adam Michael Ruff,Grecio Sandoval,Jorge Santana,Shannon M. Schlater,Frank C. Sciurba,Caitlin A. Selvaggi,Sudha Seshadri,Howard D. Sesso,Dimpy P. Shah,Eyal Shemesh,Zaki A. Sherif,Daniel J Shinnick,Hyagriv N. Simhan,Upinder Singh,A. Sowles,Vignesh Subbian,Jun Sun,Mehul S. Suthar,Larissa Teunis,John M. Thorp,Alan T.N. Tita,Robin Tragus,Katherine R. Tuttle,Alfredo E. Urdaneta,P. Utz,Timothy M. VanWagoner,A. J. Vasey,Suzanne D. Vernon,Tiffany Harris Walker,Honorine D. Ward,David E. Warren,Ryan Weeks,Steven J. Weiner,Jennifer Wheeler,Sidney W. Whiteheart,Zanthia Wiley,Natasha J. Williams,Juan P. Wisnivesky,John N. Wood,Lynn M. Yee,Natalie Young,Sokratis N Zisis,Andrea S. Foulkes +188 more
TL;DR: The Researching COVID to Enhance Recovery (RECOVER) Multi-site Observational Study of SARS-CoV-2 infection (PASC) in Adults (reCOVER-Adult) as discussed by the authors is the first large-scale longitudinal cohort of PASC among US adults.
Posted ContentDOI
ChAdOx1 nCoV-19 (AZD1222) vaccine elicits monoclonal antibodies with potent cross-neutralizing activity against SARS-CoV-2 viral variants
Rebekah Roberts,Anele Waters +1 more
TL;DR: In this article, a panel of 44 anti-SARS-CoV-2 monoclonal antibodies (mAbs) from an individual who received two doses of the ChAdOx1 nCoV19 (AZD1222) vaccine at a 12-week interval were obtained.
References
More filters
Journal ArticleDOI
Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction
TL;DR: A new method of total RNA isolation by a single extraction with an acid guanidinium thiocyanate-phenol-chloroform mixture is described, providing a pure preparation of undegraded RNA in high yield and can be completed within 4 h.
Journal ArticleDOI
A simple method for displaying the hydropathic character of a protein
Jack Kyte,Russell F. Doolittle +1 more
TL;DR: A computer program that progressively evaluates the hydrophilicity and hydrophobicity of a protein along its amino acid sequence has been devised and its simplicity and its graphic nature make it a very useful tool for the evaluation of protein structures.
Journal ArticleDOI
Virological assessment of hospitalized patients with COVID-2019.
Roman Wölfel,Victor M. Corman,Wolfgang Guggemos,M Seilmaier,Sabine Zange,Marcel A. Müller,Daniela Niemeyer,Terry Jones,Terry Jones,Patrick Vollmar,Camilla Rothe,Michael Hoelscher,Tobias Bleicker,Sebastian Brünink,Julia Schneider,Rosina Ehmann,Katrin Zwirglmaier,Christian Drosten,Clemens M. Wendtner +18 more
TL;DR: Detailed virological analysis of nine cases of coronavirus disease 2019 (COVID-19) provides proof of active replication of the SARS-CoV-2 virus in tissues of the upper respiratory tract.
Journal ArticleDOI
Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals.
Alba Grifoni,Daniela Weiskopf,Sydney I. Ramirez,Sydney I. Ramirez,Jose Mateus,Jennifer M. Dan,Jennifer M. Dan,Carolyn Rydyznski Moderbacher,Stephen A. Rawlings,Aaron Sutherland,Lakshmanane Premkumar,Ramesh Jadi,Daniel Marrama,Aravinda M. de Silva,April Frazier,Aaron F. Carlin,Jason A. Greenbaum,Bjoern Peters,Bjoern Peters,Florian Krammer,Davey M. Smith,Shane Crotty,Shane Crotty,Alessandro Sette,Alessandro Sette +24 more
TL;DR: Using HLA class I and II predicted peptide ‘megapools’, circulating SARS-CoV-2−specific CD8+ and CD4+ T cells were identified in ∼70% and 100% of COVID-19 convalescent patients, respectively, suggesting cross-reactive T cell recognition between circulating ‘common cold’ coronaviruses and SARS.
Journal ArticleDOI
Persistent Symptoms in Patients After Acute COVID-19.
TL;DR: This case series describes COVID-19 symptoms persisting a mean of 60 days after onset among Italian patients previously discharged from CO VID-19 hospitalization.
Related Papers (5)
Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection.
Jennifer M. Dan,Jennifer M. Dan,Jose Mateus,Yu Kato,Kathryn M. Hastie,Esther Dawen Yu,Caterina E. Faliti,Alba Grifoni,Sydney I. Ramirez,Sydney I. Ramirez,Sonya Haupt,April Frazier,Catherine Nakao,Vamseedhar Rayaprolu,Stephen A. Rawlings,Bjoern Peters,Bjoern Peters,Florian Krammer,Viviana Simon,Erica Ollmann Saphire,Erica Ollmann Saphire,Davey M. Smith,Daniela Weiskopf,Alessandro Sette,Alessandro Sette,Shane Crotty,Shane Crotty +26 more
Convergent antibody responses to SARS-CoV-2 in convalescent individuals.
Davide F. Robbiani,Davide F. Robbiani,Christian Gaebler,Frauke Muecksch,Julio C. C. Lorenzi,Zijun Wang,Alice Cho,Marianna Agudelo,Christopher O. Barnes,Anna Gazumyan,Shlomo Finkin,Thomas Hagglof,Thiago Y. Oliveira,Charlotte Viant,Arlene Hurley,Hans Heinrich Hoffmann,Katrina G. Millard,Rhonda G. Kost,Melissa Cipolla,Kristie Gordon,Filippo Bianchini,Spencer T. Chen,Victor A. Ramos,Roshni Patel,Juan Dizon,Irina Shimeliovich,Pilar Mendoza,Harald Hartweger,Lilian Nogueira,Maggi Pack,Jill Horowitz,Fabian Schmidt,Yiska Weisblum,Eleftherios Michailidis,Alison W. Ashbrook,Eric Waltari,John E. Pak,Kathryn E. Huey-Tubman,Nicholas Koranda,Pauline R. Hoffman,Anthony P. West,Charles M. Rice,Theodora Hatziioannou,Pamela J. Bjorkman,Paul D. Bieniasz,Paul D. Bieniasz,Marina Caskey,Michel C. Nussenzweig,Michel C. Nussenzweig +48 more
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.
Fernando P. Polack,Stephen J. Thomas,Nicholas Kitchin,Judith Absalon,Alejandra Gurtman,Stephen Lockhart,John L. Perez,Gonzalo Pérez Marc,Edson D. Moreira,Cristiano Zerbini,Ruth Bailey,Kena A. Swanson,Satrajit Roychoudhury,Kenneth Koury,Ping Li,Warren Kalina,David A. Cooper,Robert W. Frenck,Laura L. Hammitt,Özlem Türeci,Haylene Nell,Axel Schaefer,Serhat Ünal,Dina B. Tresnan,Susan Mather,Philip R. Dormitzer,Ugur Sahin,Kathrin U. Jansen,William C. Gruber +28 more
Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals.
Alba Grifoni,Daniela Weiskopf,Sydney I. Ramirez,Sydney I. Ramirez,Jose Mateus,Jennifer M. Dan,Jennifer M. Dan,Carolyn Rydyznski Moderbacher,Stephen A. Rawlings,Aaron Sutherland,Lakshmanane Premkumar,Ramesh Jadi,Daniel Marrama,Aravinda M. de Silva,April Frazier,Aaron F. Carlin,Jason A. Greenbaum,Bjoern Peters,Bjoern Peters,Florian Krammer,Davey M. Smith,Shane Crotty,Shane Crotty,Alessandro Sette,Alessandro Sette +24 more
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.
Lindsey R. Baden,Hana M. El Sahly,Brandon Essink,Karen L. Kotloff,Sharon E. Frey,Rick Novak,David Diemert,Stephen A. Spector,Nadine Rouphael,C. Buddy Creech,John W McGettigan,Shishir Khetan,Nathan Segall,Joel Solis,Adam Brosz,Carlos Fierro,Howard J. Schwartz,Kathleen M. Neuzil,Lawrence Corey,Peter B. Gilbert,Holly Janes,Dean Follmann,Mary A. Marovich,John R. Mascola,Laura Polakowski,Julie E. Ledgerwood,Barney S. Graham,Hamilton Bennett,Rolando Pajon,Conor Knightly,Brett Leav,Weiping Deng,Honghong Zhou,Shu Liang Han,Melanie Ivarsson,Jacqueline Miller,Tal Z Zaks +36 more